Sareum Announce Extension of Genentech Agreement
News Dec 13, 2007
Under the terms of this agreement, Sareum will continue to apply its skills in high throughput protein expression, purification and structure determination on drug discovery targets designated by Genentech.
In return, Sareum will receive research fees and may receive specific success-dependent milestone payments. Financial terms of the agreement were not disclosed.
Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said: “Successfully delivering on relationships with leading companies such as Genentech is a key component of our business strategy and an outstanding validation of Sareum’s technology and expertise. We are very pleased to have supported Genentech’s programs over the last 12 months, and look forward to continuing this important relationship.”
Genetic Variations in the Lungs Identify COPD RiskNews
Developmental genetic variations in the anatomy of the lung could indicate people at risk of COPD later in life, a study suggests.READ MORE
Proteasome Blocker Brings Glaucoma Gene Therapy CloserNews
An enhanced gene therapy technique that pairs a viral vector with a proteasome blockade has doubled the therapy's efficiency.READ MORE
New Class of Decoy Molecules that Prevent the Onset of PainNews
Researcher report a new method of reducing pain-associated behaviors with RNA-based medicine, creating a new class of decoy molecules that prevent the onset of pain.READ MORE